Literature DB >> 8941635

Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development.

J Shen1, E Herderick, J F Cornhill, E Zsigmond, H S Kim, H Kühn, N V Guevara, L Chan.   

Abstract

Oxidative modification of LDL increases its atherogenicity, and 15-lipoxygenase (15-LO) has been implicated in the process. To address this issue, we generated transgenic rabbits that expressed 15-LO in a macrophage-specific manner and studied their susceptibility to atherosclerosis development when they were fed a high-fat, high-cholesterol (HFHC) diet (Teklad 0533 rabbit diet 7009 with 10% corn oil and 0.25% cholesterol) for 13.5 wk. Transgenic and nontransgenic rabbits developed similar degrees of hypercholesterolemia and had similar levels of triglyceride, VLDL, LDL, and HDL. Quantitative morphometric analysis of the aortic atherosclerosis indicated that the transgenic animals (n = 19) had significantly smaller lesion areas (9.8+/-6.5%, mean+/-SD) than their littermate controls (n = 14, 17.8+/-15.0%) (P < 0.05). In a subgroup (n = 9) of transgenic rabbits that received the HFHC diet plus the antioxidant N',N '-diphenyl-phenylenediamine (1%), the extent of lesion involvement (9.8+/-7.5%) did not differ from the subgroup (n = 10) that received the regular HFHC diet (9.7+/-5.9%). Since the results were unexpected, we repeated the experiments. Again, we found that the nontransgenic littermates (n = 12) had more extensive lesions (11.6+/-10.6%) than the transgenic rabbits (n = 13; 9.5+/-7.8%), although the difference was not significant. In a third set of experiments, we crossed 15-LO transgenic rabbits with Watanabe heritable hyperlipidemic (WHHL) rabbits and found that the lesion area in the 15-LO transgenic/heterozygous WHHL rabbits (n = 14) was only about one third (7.7+/-5.7%) that found in nontransgenic heterozygous WHHL littermate controls (n = 11, 20.7+/-19.4%) (P < 0.05). These data suggest that overexpression of 15-LO in monocytes/macrophages protects against lipid deposition in the vessel wall during early atherogenesis in these rabbit models of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8941635      PMCID: PMC507668          DOI: 10.1172/JCI119029

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  The binding of monomeric IgG to human blood monocytes and alveolar macrophages.

Authors:  M D Rossman; P Chien; A Cassizzi-Cprek; J A Elias; A Holian; A D Schreiber
Journal:  Am Rev Respir Dis       Date:  1986-02

2.  Selected methodologic aspects of the International Atherosclerosis Project.

Authors:  M A Guzmán; C A McMahan; H C McGill; J P Strong; C Tejada; C Restrepo; D A Eggen; W B Robertson; L A Solberg
Journal:  Lab Invest       Date:  1968-05       Impact factor: 5.662

3.  Endothelial cells produce a lipoxygenase derived chemo-repellent which influences platelet/endothelial cell interactions--effect of aspirin and salicylate.

Authors:  M R Buchanan; R W Butt; Z Magas; J van Ryn; J Hirsh; D J Nazir
Journal:  Thromb Haemost       Date:  1985-06-24       Impact factor: 5.249

4.  13-Hydroxyoctadecadienoic acid (13-HODE) stimulates prostacyclin production by endothelial cells.

Authors:  B N Setty; M Berger; M J Stuart
Journal:  Biochem Biophys Res Commun       Date:  1987-07-31       Impact factor: 3.575

5.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.

Authors:  T E Carew; D C Schwenke; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

6.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.

Authors:  T Kita; Y Nagano; M Yokode; K Ishii; N Kume; A Ooshima; H Yoshida; C Kawai
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  Transgenic rabbits with the integrated human 15-lipoxygenase gene driven by a lysozyme promoter: macrophage-specific expression and variable positional specificity of the transgenic enzyme.

Authors:  J Shen; H Kühn; A Petho-Schramm; L Chan
Journal:  FASEB J       Date:  1995-12       Impact factor: 5.191

8.  Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits.

Authors:  M E Haberland; D Fong; L Cheng
Journal:  Science       Date:  1988-07-08       Impact factor: 47.728

9.  13-Hydroxyoctadecadienoic acid is the vessel wall chemorepellant factor, LOX.

Authors:  M R Buchanan; T A Haas; M Lagarde; M Guichardant
Journal:  J Biol Chem       Date:  1985-12-25       Impact factor: 5.157

10.  13-Hydroxyoctadeca-9,11-dienoic acid (13-HODE) inhibits thromboxane A2 synthesis, and stimulates 12-HETE production in human platelets.

Authors:  B N Yamaja Setty; M Berger; M J Stuart
Journal:  Biochem Biophys Res Commun       Date:  1987-10-29       Impact factor: 3.575

View more
  68 in total

1.  At last, direct evidence that lipoxygenases play a role in atherogenesis.

Authors:  D Steinberg
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

Review 2.  Effects of antioxidants against atherosclerosis.

Authors:  Etsuo Niki; Noriko Noguchi
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

3.  PPARs and lipid ligands in inflammation and metabolism.

Authors:  Gregory S Harmon; Michael T Lam; Christopher K Glass
Journal:  Chem Rev       Date:  2011-10-12       Impact factor: 60.622

4.  Two single nucleotide polymorphisms in ALOX15 are associated with risk of coronary artery disease in a Chinese Han population.

Authors:  Kai Zhang; Yuan-yuan Wang; Qi-ji Liu; Hui Wang; Fang-fang Liu; Zhi-yong Ma; Yao-qin Gong; Li Li
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

Review 5.  Functional and pathological roles of the 12- and 15-lipoxygenases.

Authors:  Anca D Dobrian; David C Lieb; Banumathi K Cole; David A Taylor-Fishwick; Swarup K Chakrabarti; Jerry L Nadler
Journal:  Prog Lipid Res       Date:  2010-10-21       Impact factor: 16.195

6.  Monocyte 15-lipoxygenase gene expression requires ERK1/2 MAPK activity.

Authors:  Ashish Bhattacharjee; Anny Mulya; Srabani Pal; Biswajit Roy; Gerald M Feldman; Martha K Cathcart
Journal:  J Immunol       Date:  2010-09-22       Impact factor: 5.422

Review 7.  Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins.

Authors:  Matthew Spite; Charles N Serhan
Journal:  Circ Res       Date:  2010-11-12       Impact factor: 17.367

8.  15-Lipoxygenase 1 interacts with phosphatidylethanolamine-binding protein to regulate MAPK signaling in human airway epithelial cells.

Authors:  Jinming Zhao; Valerie B O'Donnell; Silvana Balzar; Claudette M St Croix; John B Trudeau; Sally E Wenzel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-09       Impact factor: 11.205

9.  ROS-dependent Syk and Pyk2-mediated STAT1 activation is required for 15(S)-hydroxyeicosatetraenoic acid-induced CD36 expression and foam cell formation.

Authors:  Sivareddy Kotla; Nikhlesh K Singh; James G Traylor; A Wayne Orr; Gadiparthi N Rao
Journal:  Free Radic Biol Med       Date:  2014-08-23       Impact factor: 7.376

10.  Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury.

Authors:  Alexander J Leedom; Aaron B Sullivan; Baiyan Dong; Denise Lau; Karsten Gronert
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.